Vimian operates within the global animal health market, historically characterised by strong, resilient, and non-cyclical growth. Market development is supported by a number of attractive underlying and secular growth drivers; increase in pet ownership, the humanisation of pets, the increased awareness of available products and treatments for companion animals, as well an aging pet population.

Vimian targets global niches of this market with particular unmet medical needs and sustainable above-market growth potential. The company believes that its addressable market will increase to EUR 45 billion by 2030, corresponding to around 7 per cent CAGR 2023-2030.

Vimian has a history of high and profitable growth. From 2018 to 2023, the Company demonstrated 67 per cent revenue growth CAGR reaching pro-forma LTM revenue of EUR 335 million and adjusted EBITA CAGR growth of 87 per cent reaching EUR 89 million for the twelve months ending 31 December, 2023. Organic growth reached 11 per cent in 2023. 

Vimian partners with exceptional entrepreneurs and management teams to support accelerated innovation and growth. Between 2015 - 2023, with a selective approach to M&A, Vimian has successfully completed 48 acquisitions in more than 15 countries across Europe, North America and APAC.

Vimian brings businesses with a strong industrial logic together to complement its product portfolios, access new geographies, customer bases and new technologies. The market remains highly fragmented, and Vimian believes there are significant opportunities for further value-creative M&A. 

The asset-light nature of Vimian’s business, with Capex (excl. acquisitions) of c. 4–5 per cent of revenue and net working capital of c. 20 per cent of proforma revenue, supports strong cash flow generation.

The new financial target, adopted in March 2024, of annual adjusted EBITA above EUR 300m by 2030, reflects Vimian’s ambition to build shareholder value through strong profit growth with a high level of cash generation.